13F Holdings
中文EN

PBLS Parabilis Medicines, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1657677 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio12.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$2.11M$148,000—$0$0—
R&D expense$45.60M$39.38M—$28.20M$30.13M—
SG&A expense$11.25M$11.66M—$6.65M$6.39M—
Operating income-$54.74M-$50.89M—-$34.84M-$36.52M—
Interest expense$124,000$210,000—$398,000$396,000—
Net income-$44.49M-$52.46M-$45.32M-$33.48M-$34.81M-$38.33M
EBITDA-$54.14M-$50.29M—-$34.74M-$36.32M—
EPS (basic)-0.36-2.32—-21.66-22.28—
EPS (diluted)-0.36-2.32—-21.66-22.28—
Weighted avg. shares (diluted)123.59M28.91M—2.03M2.02M—
Balance sheet
Cash & equivalents$521.20M$1.09B—$57.40M$80.39M—
Short-term investments$350.43M$33.64M————
Receivables$443,000—————
Current assets$879.02M$1.13B————
PP&E, net$9.51M$6.72M————
Total assets$1.13B$1.18B————
Current liabilities$68.26M$62.84M————
Short-term debt$2.00M$5.71M————
Long-term debt—$700,000————
Total debt—$6.41M————
Total liabilities$126.89M$127.53M————
Shareholders' equity$1.00B$1.05B-$570.32M-$488.05M-$455.41M-$421.43M
Net debt—-$1.08B————
Shares outstanding122.08M121.94M————
Cash flow statement
Operating cash flow-$41.08M——-$31.54M——
Capital expenditure$611,000——$93,000——
Free cash flow-$41.69M——-$31.63M——
Investing cash flow-$518.28M——$8.68M——
Financing cash flow-$6.50M——-$137,000——
Depreciation & amortization$600,000$600,000—$100,000$200,000—
Stock-based compensation$2.74M$3.63M—$820,000$823,000—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.